17 Aug EPOETIN ALFA – New warnings on severe cutaneous adverse reaction
Posted at 13:00h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), JANSSEN PHARMACEUTICA (PTY) LTD, would like to inform you of the risk of severe cutaneous adverse reactions in patients treated with Eprex®.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
11/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals